moxifloxacin has been researched along with chloroquine in 12 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (chloroquine) | Trials (chloroquine) | Recent Studies (post-2010) (chloroquine) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 16,405 | 763 | 4,029 |
| Protein | Taxonomy | moxifloxacin (IC50) | chloroquine (IC50) |
|---|---|---|---|
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | 43 | |
| Spike glycoprotein | Betacoronavirus England 1 | 5.47 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 5.47 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 5.47 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0301 | |
| Amyloid-beta precursor protein | Homo sapiens (human) | 7 | |
| Histidine-rich protein PFHRP-II | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2383 | |
| Procathepsin L | Homo sapiens (human) | 5.47 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 5.47 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Spike glycoprotein | Severe acute respiratory syndrome coronavirus 2 | 3.58 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.375 | |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 1.5 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.27 | |
| Beta-secretase 1 | Homo sapiens (human) | 7 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 2.503 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 6.235 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.02 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Anquetin, G; Derouin, F; Farhati, K; Gozalbes, R; Greiner, J; Guedj, R; Mahmoudi, N; Rouquayrol, M; Santillana-Hayat, M; Vierling, P | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Anquetin, G; Biot, C; Dive, D; Dubar, F; Khalife, J; Pradines, B | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chibale, K; Franzblau, SG; Guantai, EM; Gut, J; Hans, RH; Lategan, C; Rosenthal, PJ; Smith, PJ; Wan, B | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Sen, S; Sinha, N | 1 |
| Chibale, K; Franzblau, SG; Gut, J; Hans, RH; Rosenthal, PJ; van Helden, PD; Wan, B; Wiid, IJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dana, S; Dhar, SK; Gurung, SK; Kumar, S; Mondal, N; Mukhopadhyay, P; Valissery, P | 1 |
| Beberok, A; Boryczka, S; Marciniec, K; Pęcak, P; Wrześniok, D | 1 |
1 review(s) available for moxifloxacin and chloroquine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
11 other study(ies) available for moxifloxacin and chloroquine
| Article | Year |
|---|---|
Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.
Topics: Animals; Antimalarials; Antiparasitic Agents; Cell Line; Drug Design; Fibroblasts; Fluoroquinolones; Humans; Inhibitory Concentration 50; Plasmodium; Quantitative Structure-Activity Relationship; Toxoplasma | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
Topics: Aminoquinolines; Antimalarials; Ciprofloxacin; Ferrous Compounds; Metallocenes; Plasmodium falciparum; Prodrugs | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Synthesis, antimalarial and antitubercular activity of acetylenic chalcones.
Topics: Alkynes; Antimalarials; Antitubercular Agents; Chalcones; Mycobacterium tuberculosis; Plasmodium falciparum | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents.
Topics: Animals; Antimalarials; Antitubercular Agents; Isatin; Lactones; Mycobacterium tuberculosis; Plasmodium falciparum; Structure-Activity Relationship | 2011 |
Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity.
Topics: | 2020 |
Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis.
Topics: Antiviral Agents; Binding Sites; Chloroquine; Ciprofloxacin; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Moxifloxacin; Nelfinavir; Protein Binding; SARS-CoV-2 | 2020 |